{'fraction_non_alphanumeric': 0.03264925373134328, 'fraction_numerical': 0.017723880597014924, 'mean_word_length': 5.745283018867925, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Evaluation of Production and Characterization of Monoclonal Antibodies to Human IgG of Four Subclasses

Human IgG of four subclasses, semi‐purified from pooled human serum by a series of DEAE ion exchange and protein A affinity chromatographies, were used as immunogens and initial screening antigens to produce subclass‐specific and ‐restricted monoclonal antibodies (McAbs). These McAbs were bound to CNBr‐activated Sepharose 4B and utilized in immunoaffinity chromatography to prepare four polyclonal human IgG subclasses of satisfactory purities, which were then used as final screening antigens. Subclass‐specific McAbs thus chosen were further evaluated for subclass‐ and especially allotype‐specificity using a panel of monoclonal IgG myeloma proteins with representative Gm markers for each subclass in micro enzyme‐linked immunosorbent assay (ELISA). A total of 10 clones of subclass‐specific McAbs (one for anti‐IgG1, three anti‐IgG2, two anti‐IgG3, four anti‐IgG4) were established. Among them, IgG2‐specific clones of HG2‐30F and HG2‐56F, IgG3‐specific HG3‐7C and HG3‐32C, and IgG4‐specific HG4‐53G McAbs were superior to the corresponding specificity standard McAbs chosen by the Human Immunoglobulins Subcommittee of the WHO/International Union of Immunological Societies (IUIS) in 1985. As allotype‐specific McAbs, HG1‐1E for Glm(az) and HG3‐3B for G3m(b) were obtained. In micro ELISA of this study as well as all protocols of the previous WHO/IUIS collaborative study, antigens (myeloma IgG subclasses) were immobilized or fixed to a solid phase, resulting in possible variations in their epitope expressions. We developed a new assay system, micro radioimmunoassay (RIA), in which reactivities of McAbs against free IgG subclasses in solution can be evaluated. HG2‐30F, having extremely high reactivities to coated IgG2 in micro ELISA, remarkably reduced its reactivities to free IgG2 in solution in micro RIA. Two other clones also showed some different reactivities in micro RIA and micro ELISA. We believe that this micro RIA is valuable for evaluation of McAbs reactivities against native human IgG subclasses in solution.